Decade-Long Misconduct Case Closed

A former University of Washington researcher did commit misconduct 10 years ago, according to the Office of Research Integrity.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, JOHN LESTERAfter 10 years of inquiry, including multiple investigations by the University of Washington and the federal government, the Office of Research Integrity (ORI) has made its final ruling: Andrew Aprikyan committed misconduct, falsifying results to studies supported by a handful of federal grants and published in two papers, one of which has been retracted.

The investigations started in 2003, when errors were identified in a paper Aprikyan had published in Blood reporting his research on the blood disorder neutropenia. The university opened an investigation at that time, which after 3 years concluded that Aprikyan had falsified seven figures and tables in the Blood paper and another publication in Experimental Hematology, which was never retracted but was issued an erratum in 2006. Aprikyan denied any wrongdoing and even convinced the university to reopen the investigation, which, after another 2 years, concluded there was no evidence of misconduct. Nevertheless, the university fired him in May 2010, arguing that the second investigative panel did not have the necessary authority to reopen the case.

Now, nearly 3 years later, the ORI finally weighs ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio